YAP1 and Hepatic fibrosis: Pharmacological inhibition of either PAK or YAP1 markedly ameliorates experimental liver fibrosis, with PAK inhibitors producing the most rapid suppression of the myofibroblast phenotype and limiting postinjury scar expansion [350].